Stockscreener 앱 받기
42.48
1.26%
0.53
Soleno Therapeutics Inc 주식(SLNO)의 최신 뉴스
Momentum Shift: What is Soleno Therapeutics Incs revenue forecast2025 Year in Review & Consistent Growth Equity Picks - baoquankhu1.vn
Market Outlook: Is Soleno Therapeutics Inc forming a breakout patternJuly 2025 Momentum & Long Hold Capital Preservation Plans - baoquankhu1.vn
Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid - GlobeNewswire
Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid Disappointing VYKAT XR Starts, Discontinuations; Shares Down 26% -- Hagens Berman - GlobeNewswire Inc.
Soleno Therapeutics (SLNO) may find a bottom soon, here's why you should buy the stock now - MSN
Dow Update: Is Monogram Technologies Inc trading at a discountWeekly Stock Summary & Precise Entry and Exit Recommendations - baoquankhu1.vn
Q4 EPS Estimate for Soleno Therapeutics Increased by Analyst - MarketBeat
Soleno Therapeutics (SLNO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Finviz
Soleno Therapeutics: Why I’m Staying On The Sidelines (NASDAQ:SLNO) - Seeking Alpha
Jobs Data: Is Soleno Therapeutics Inc in a bullish channel2025 Earnings Impact & Trade Opportunity Analysis - baoquankhu1.vn
Relative Strength Alert For Soleno Therapeutics - Nasdaq
Cantor Fitzgerald reiterates Overweight rating on Soleno Therapeutics stock By Investing.com - Investing.com Nigeria
Cantor Fitzgerald reiterates Overweight rating on Soleno Therapeutics stock - Investing.com
A Look At Soleno Therapeutics (SLNO) Valuation After Profitable Q4 2025 And VYKAT XR Adoption - Sahm
Baird lowers Soleno Therapeutics stock price target to $107 on new starts trajectory - Investing.com Nigeria
Wall Street Recap: Will Soleno Therapeutics Inc. stock see insider buyingWeekly Investment Summary & Reliable Breakout Forecasts - Bộ Nội Vụ
Soleno Therapeutics (NASDAQ:SLNO) Hits New 1-Year LowTime to Sell? - MarketBeat
Soleno Therapeutics stock hits 52-week low at 41.47 USD By Investing.com - Investing.com Nigeria
Soleno reports $189-191 million in 2025 VYKAT XR sales since launch - Investing.com Nigeria
SLNO Investors: Contact Kirby McInerney LLP About Investigation into Soleno Therapeutics, Inc. - marketscreener.com
Soleno Therapeutics (NASDAQ:SLNO) Shares Gap UpTime to Buy? - MarketBeat
Soleno Therapeutics stock falls despite revenue beat as patient starts decline - Investing.com UK
Rally Mode: Will Soleno Therapeutics Inc stock deliver shareholder valueWeekly Investment Report & Technical Entry and Exit Tips - Bộ Nội Vụ
Soleno Therapeutics stock hits 52-week low at 41.47 USD - Investing.com
Soleno Therapeutics up on forecasting preliminary 2025 Vykat XR sales above estimates - TradingView — Track All Markets
Soleno Therapeutics, Inc. (SLNO) Stock Analysis: A Potential Upside of 164% Captures Investor Attention - DirectorsTalk Interviews
Soleno Therapeutics Announces Select Preliminary Fourth Quarter and Full-Year 2025 Results - The Manila Times
Market Review: Why Soleno Therapeutics Inc stock is popular among millennialsWeekly Profit Report & Long-Term Capital Growth Strategies - moha.gov.vn
Peregrine Capital Management LLC Makes New Investment in Soleno Therapeutics, Inc. $SLNO - MarketBeat
Soleno Therapeutics, Inc.Common Stock (NQ: SLNO - FinancialContent
Soleno Therapeutics (SLNO) among stocks that will bounce back according to analysts - MSN
SLNO Investigation: Investors Encouraged to Contact Kirby McInerney LLP - Bluefield Daily Telegraph
Soleno Therapeutics (NASDAQ:SLNO) Trading Down 4.2%What's Next? - MarketBeat
Why Soleno Therapeutics stock is down today: investor alerts revive Vykat XR scrutiny - TechStock²
Will Peer‑Reviewed VYKAT XR Data Calm Safety Debate And Change Soleno Therapeutics' (SLNO) Narrative? - Sahm
Soleno Therapeutics (SLNO) Among Stocks That Will Bounce Back According to Analysts - Insider Monkey
Why Soleno Therapeutics Inc. stock is popular among millennialsWeekly Investment Report & Safe Entry Momentum Stock Tips - ulpravda.ru
Assessing Soleno Therapeutics (SLNO) Valuation After JCEM VYKAT XR Data And FDA Approval - Yahoo Finance
Macro Review: Can Soleno Therapeutics Inc. stock hit record highs againJuly 2025 Short Interest & Expert Curated Trade Setups - ulpravda.ru
Can Soleno Therapeutics Inc. stock hit record highs again2025 Major Catalysts & Smart Investment Allocation Tips - ulpravda.ru
Bragar Eagel & Squire, P.C. Encourages Soleno, Avita, and Coty Investors to Contact the ... - Bluefield Daily Telegraph
Bragar Eagel & Squire, P.C. Encourages Soleno, Avita, and - GlobeNewswire
12 Stocks that Will Bounce Back According to Wall Street Analysts - Insider Monkey
Will Soleno Therapeutics Inc. stock deliver strong dividend growthQuarterly Profit Review & Expert Curated Trade Setup Alerts - ulpravda.ru
What technical signals suggest for Soleno Therapeutics Inc. stockOil Prices & Weekly Setup with ROI Potential - ulpravda.ru
Does Soleno Therapeutics Inc. stock trade at a discount to peersWeekly Stock Report & Weekly High Return Opportunities - ulpravda.ru
Soleno Therapeutics announces entry into $100M accelerated share repurchase agreement - MSN
Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics - Yahoo Finance
Soleno Therapeutics (SLNO) Receives a Buy from Wells Fargo - The Globe and Mail
Is Soleno Therapeutics Inc. stock supported by strong fundamentalsEconomic Data Impact & Market-Leading Growth Rates - ulpravda.ru
Soleno Therapeutics (NASDAQ:SLNO) Upgraded by Zacks Research to "Strong-Buy" Rating - MarketBeat
Do You Believe in the Growth Prospects of Soleno Therapeutics (SLNO)? - Finviz
Wells Fargo Reiterates a Buy Rating on Soleno Therapeutics (SLNO), Sets a PT of $123 - MSN
Soleno’s PWS treatment study results published in endocrinology journal By Investing.com - Investing.com Nigeria
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc.SLNO - Chartmill
4.73%
0.92%
자본화:
|
볼륨(24시간):